CIK 0001678660
- Non-accelerated filer
- Smaller reporting company
Prelude Therapeutics Inc
Sign in to watch- Ticker
- PRLD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811384762
- Phone
- +1 302-467-1280
- Business address
- 175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805
- Former names
- Prelude Therapeutics Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-04 | Scherle Peggy Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +230,000 | 230,000 | ||
| 2025-02-04 | Scherle Peggy Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +175,000 | 175,000 | ||
| 2024-03-01 | Scherle Peggy Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2023-02-07 | Scherle Peggy Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +135,000 | 135,000 | ||
| 2022-02-15 | Scherle Peggy Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2021-08-27 | Scherle Peggy Chief Scientific Officer | Exercise or conversion | +6,014 | $1.43 | $9K | 178,934 |
| 2021-08-27 | Scherle Peggy Chief Scientific Officer | Sale | −2,700 | $35.32 | $95K | 176,234 |
| 2021-08-27 | Scherle Peggy Chief Scientific Officer | Sale | −2,707 | $36.23 | $98K | 173,527 |
| 2021-08-27 | Scherle Peggy Chief Scientific Officer | Sale | −607 | $37.08 | $23K | 172,920 |
| 2021-08-27 | Scherle Peggy Chief Scientific Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −6,014 | 27,018 | ||
| 2021-08-26 | Scherle Peggy Chief Scientific Officer | Exercise or conversion | +1,700 | $1.43 | $2K | 174,620 |
| 2021-08-26 | Scherle Peggy Chief Scientific Officer | Sale | −1,700 | $35.19 | $60K | 172,920 |
| 2021-08-26 | Scherle Peggy Chief Scientific Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −1,700 | 33,032 | ||
| 2021-08-13 | Scherle Peggy Chief Scientific Officer | Exercise or conversion | +558 | $1.89 | $1K | 173,478 |
| 2021-08-13 | Scherle Peggy Chief Scientific Officer | Exercise or conversion | +1,728 | $1.43 | $2K | 175,206 |
| 2021-08-13 | Scherle Peggy Chief Scientific Officer | Sale | −2,286 | $35.07 | $80K | 172,920 |
| 2021-08-13 | Scherle Peggy Chief Scientific Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −558 | 42,672 | ||
| 2021-08-13 | Scherle Peggy Chief Scientific Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −1,728 | 34,732 | ||
| 2021-07-27 | Scherle Peggy Chief Scientific Officer | Exercise or conversion | +20,000 | $1.43 | $29K | 192,920 |
| 2021-07-27 | Scherle Peggy Chief Scientific Officer | Sale | −19,320 | $35.45 | $685K | 173,600 |
Page 1 of 2 · 39 trades